Novo Nordisk, the world's largest insulin maker, will cut as many as 180 jobs as the company stops research into non-biotechnology treatments.
Research and development will focus on exclusively on protein-based drugs, Bagsvaerd, Denmark-based Novo Nordisk said today in a statement to the Copenhagen stock exchange. Current projects in so-called "small molecules" will be disposed, the company said.
Bloomberg
No comments:
Post a Comment